Spero Therapeutics receives Nasdaq bid price deficiency notice; has until Aug 25, 2025 to regain compliance

Spero Therapeutics, Inc.

Nasdaq notified Spero on Feb 25, 2025 that its stock closed below $1.00 for 30 consecutive trading days.
Compliance deadline is August 25, 2025; cure requires closing at $1.00+ for 10 consecutive business days.
If not cured, Spero may transfer to Nasdaq Capital Market and consider reverse stock split for 180-day extension.
Stock continues trading on Nasdaq GS under SPRO; no immediate delisting effect.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.